Olopatadine
Brand names: Opatanol, Patanase
Olopatadine is a topical antihistamine, available as eye drops and a nasal spray, used to relieve the symptoms of allergic conjunctivitis and allergic rhinitis.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It is a selective histamine H1-receptor antagonist with mast cell stabilising activity, reducing the release and effects of histamine and other mediators of the allergic response.
Prescribing in practice
- Ophthalmic preparations containing benzalkonium chloride should not be used while soft contact lenses are in place; lenses can be reinserted after a short interval.
- Transient stinging, blurred vision or an unpleasant taste may occur after application.
- It treats allergic symptoms and does not address the underlying allergen exposure.
Monitoring
No routine monitoring is required; review if allergic symptoms remain poorly controlled.
Counselling the patient
- If you wear soft contact lenses, remove them before using the eye drops and wait before reinserting.
- Brief stinging or blurring after use is common and usually settles quickly.
- Avoid touching the dropper tip to the eye to prevent contamination.
Evidence & guidelines
Use is supported by its established role in topical treatment of allergic conjunctivitis and rhinitis; see current prescribing references.
Reference: BSACI; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Urticaria Activity Score (UAS7) · Urticaria
- C-Peptide to Glucose Ratio · Diabetes Classification
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- International Prognostic Index (IPI) for DLBCL · Lymphoma
- IMDC Risk Model for Metastatic Renal Cell Carcinoma · Cancer Prognosis
- HCT-CI — Haematopoietic Cell Transplant Comorbidity Index · Risk Stratification
- Acute Red Eye / Vision Loss Screen · RCOphth 2020; NICE CKS
- Idiopathic Intracranial Hypertension · ABN; consensus 2018
- Acute Red Eye Assessment · RCOphth / AAO
- Acute Angle Closure Glaucoma · RCOphth / EGS Guidelines
- Retinal Detachment · RCOphth Guidelines / EURETINA
- Diabetic Retinopathy — Screening and Management · NICE NG28 2016 / NHS DES Programme